Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14558308 | 0.88 | SSTR4 (0.35) | SSTR4AAK1SIRT2IRAK4HTR2C | |
| SCHEMBL5337903 | 0.87 | CHRNB2 (0.31) | SSTR4SIRT2IRAK4 | |
| SCHEMBL5428116 | 0.87 | SSTR4 (0.34) | SSTR4AAK1SIRT2IRAK4HTR2C | |
| SCHEMBL5345555 | 0.83 | SSTR4 (0.31) | SSTR4AAK1SIRT2 | |
| SCHEMBL5348846 | 0.83 | TRPV3 (0.34) | TRPV3SIRT2 | |
| SCHEMBL5342203 | 0.83 | SSTR4 (0.32) | SSTR4AAK1TRPV3SIRT2IRAK4 | |
| SCHEMBL7246522 | 0.81 | CHRNB2 (0.36) | TRPV3 | |
| SCHEMBL14558307 | 0.80 | MAPT (0.32) | SSTR4AAK1SIRT2IRAK4 | |
| SCHEMBL3511518 | 0.78 | HTR2C (0.45) | SSTR4HTR2CSLC6A4 | |
| SCHEMBL5354963 | 0.74 | XIAP (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1619184-A2 | Urea compounds as kinase inhibitors | Amgen, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1392306-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Aventis Pharma Limited (GB) | 2004-03-03 | — | — | EP | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| EP-1309589-A2 | UREA COMPOUNDS AND METHODS OF USES | Amgen Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002098426-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | AVENTIS PHARMA LIMTIED (GB) | 2002-12-12 | — | — | WO | disclosed |
| US-20020173507-A1 | Urea compounds and methods of uses | AMGEN INC. | 2002-11-21 | — | — | US | disclosed |
| WO-2002014311-A2 | UREA COMPOUNDS AND METHODS OF USES | AMGEN INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | SSTR4 2822/4885AAK1 1295/4885TRPV3 3414/4885 |
| US-20020173507-A1 | Urea compounds and methods of uses | SLC14A1, UMPS, BAX | SSTR4 3309/4885AAK1 2502/4885TRPV3 4231/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | SSTR4 2822/4885AAK1 1295/4885TRPV3 3414/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | SSTR4 2822/4885AAK1 1295/4885TRPV3 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.